Kairos Pharma (NYSEAMERICAN:KAPA) Shares Down 4.2% – Here’s Why

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA)’s stock price traded down 4.2% on Tuesday . The stock traded as low as $0.4303 and last traded at $0.4310. 85,238 shares traded hands during trading, a decline of 52% from the average session volume of 176,798 shares. The stock had previously closed at $0.45.

Kairos Pharma Trading Up 6.6%

The company has a fifty day moving average price of $0.54 and a two-hundred day moving average price of $0.65. The company has a market cap of $9.81 million, a price-to-earnings ratio of -1.53 and a beta of 1.36.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter. Sell-side analysts anticipate that Kairos Pharma, Ltd. will post -0.37 EPS for the current fiscal year.

Institutional Trading of Kairos Pharma

Institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in Kairos Pharma in the third quarter valued at $27,000. XTX Topco Ltd grew its position in Kairos Pharma by 290.8% in the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after acquiring an additional 36,086 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Kairos Pharma in the third quarter valued at $54,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.